20-year risks of breast-cancer recurrence after stopping endocrine therapy at 5 years

MLA

Pan, H., et al. “20-Year Risks of Breast-Cancer Recurrence after Stopping Endocrine Therapy at 5 Years.” New England Journal of Medicine, vol. 377, no. 19, Nov. 2017. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....04b62ad4896ceae9340b3eec35801d95&authtype=sso&custid=ns315887.

APA

Pan, H., Gray, R., Braybrooke, J., Davies, C., Taylor, C., Mcgale, P., Peto, R., Pritchard, K., Bergh, J., Dowsett, M., Hayes, D., Albain, K., Anderson, S., Arriagada, R., Barlow, W., Bartlett, J., Bergsten, nordström, E., Bliss, J., Boccardo, F., … Caffier, H. (2017). 20-year risks of breast-cancer recurrence after stopping endocrine therapy at 5 years. New England Journal of Medicine, 377(19).

Chicago

Pan, H, R Gray, J Braybrooke, C Davies, C Taylor, P Mcgale, R Peto, et al. 2017. “20-Year Risks of Breast-Cancer Recurrence after Stopping Endocrine Therapy at 5 Years.” New England Journal of Medicine 377 (19). http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....04b62ad4896ceae9340b3eec35801d95&authtype=sso&custid=ns315887.